| Name | Title | Contact Details |
|---|
Ionetix Corporation is a pioneering radiopharmaceutical end to end solutions provider for cardiac PET. Cardiac PET with Ammonia N-13.
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.
Clinical ink is the global life science company that brings data, technology, and patient-centric research together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.
Nanogenix Inc. is a biotechnology company that focuses on developing and commercializing novel cancer therapies for patients in high unmet need disease categories.
Mar Cor Purification/Fluid Solutions is a Drexel Hill, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.